Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) ongoing; top-line results on track for 2H’25Phase 3 CAPTIVATE trial of ...

Phase 3 CAPTIVATE CIDP trial ongoing ... but not limited to, that preclinical testing of DNTH103 and data from clinical trials may not be predictive of the results or success of ongoing or ...

US-based biotechnology company Seismic Therapeutic has dosed the initial cohort of healthy participants in a randomised Phase ...

Phase 3 CAPTIVATE CIDP trial ongoing: The CAPTIVATE trial is a single ... but not limited to, that preclinical testing of DNTH103 and data from clinical trials may not be predictive of the results or ...

These include myasthaenia gravis, chronic inflammatory demyelinating polyneuropathy and immune thrombocytopaenia. Seismic Therapeutic plans to test the drug's efficacy as a chronic and acute ...

Netherlands biotech Argenx has a second FDA approval for its FcRn inhibitor Vyvgart Hytrulo, adding a new indication in chronic inflammatory demyelinating polyneuropathy (CIDP) for a drug that it ...

Hunters are advised to take precautions when handling deer carcasses and to submit samples for testing. A farmed white-tail deer from Osceola County has been infected with chronic wasting disease ...

The immune molecule TGFβ has been found to weaken immune defences against latent viruses, triggering reactivation of the Epstein–Barr virus. This mechanism links TGFβ release in SARS-CoV-2 ...